MX2020007049A - Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus. - Google Patents

Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.

Info

Publication number
MX2020007049A
MX2020007049A MX2020007049A MX2020007049A MX2020007049A MX 2020007049 A MX2020007049 A MX 2020007049A MX 2020007049 A MX2020007049 A MX 2020007049A MX 2020007049 A MX2020007049 A MX 2020007049A MX 2020007049 A MX2020007049 A MX 2020007049A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
coronavirus infection
protease activity
peptides
Prior art date
Application number
MX2020007049A
Other languages
English (en)
Inventor
Ágústa Gudmundsdóttir
Bjarki Stefánsson
Gunnar Birgir Sandholt
Original Assignee
Enzymatica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymatica Ab filed Critical Enzymatica Ab
Publication of MX2020007049A publication Critical patent/MX2020007049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención proporciona un polipéptido que tiene actividad de proteasa para su uso en el tratamiento o la prevención de la infección por coronavirus en un mamífero. En particular, la invención se refiere al tratamiento o prevención de una infección por coronavirus en un ser humano, mediante el uso de tripsinas.
MX2020007049A 2018-01-08 2019-01-07 Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus. MX2020007049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1800274.1A GB201800274D0 (en) 2018-01-08 2018-01-08 Novel treatments
PCT/EP2019/050266 WO2019135003A1 (en) 2018-01-08 2019-01-07 Peptides having protease activity for use in the treatment or prevention of coronavirus infection

Publications (1)

Publication Number Publication Date
MX2020007049A true MX2020007049A (es) 2020-09-09

Family

ID=61190260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007049A MX2020007049A (es) 2018-01-08 2019-01-07 Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.

Country Status (12)

Country Link
US (1) US20200353060A1 (es)
EP (1) EP3737407A1 (es)
JP (1) JP2021509809A (es)
KR (1) KR20200107958A (es)
CN (1) CN111565743A (es)
AU (1) AU2019205602A1 (es)
BR (1) BR112020013790A2 (es)
CA (1) CA3087214A1 (es)
GB (1) GB201800274D0 (es)
MX (1) MX2020007049A (es)
RU (1) RU2020123357A (es)
WO (1) WO2019135003A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021183918A1 (en) * 2020-03-13 2021-09-16 Cmtx Biotech Inc. Methods of treating illnesses caused by coronavirus, swine flu and avian flu
US11441261B2 (en) * 2020-09-10 2022-09-13 WABESO Enhanced Enzymatics, Inc. Self-sterilizing fabrics incorporating anti-viral cold-active proteases
GB202017605D0 (en) * 2020-11-06 2020-12-23 Smarti Env Ltd biocidal Composition
KR102625620B1 (ko) * 2020-12-30 2024-01-17 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 항 코로나 바이러스용 약학적 조성물
CN114762694B (zh) * 2021-01-13 2023-07-14 中国人民解放军军事科学院军事医学研究院 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
KR102521036B1 (ko) 2021-01-15 2023-04-18 주식회사 더원 배지 및 qr코드를 이용한 코로나 바이러스 예방 접종 확인 서비스 제공방법
US20240173387A1 (en) * 2021-08-03 2024-05-30 Zymiq Technology Ab Peptidase formulation for treatment of microbial infections in the upper respiratory tract
CN113480630B (zh) * 2021-08-17 2022-06-21 贵州师范大学 一种长翼蝠来源抗菌肽ms-cath及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US20060134641A1 (en) * 1992-05-22 2006-06-22 Franklin Richard L Treating viral infections with krill enzymes
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
WO2000078332A2 (en) * 1999-06-18 2000-12-28 Jon Bragi Bjarnason Fish serine proteinases and their pharmaceutical and cosmetic use
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
GB201405784D0 (en) 2014-03-31 2014-05-14 Enzymatica Ab Novel methods, polypeptides and uses thereof
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
GB201701315D0 (en) * 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments

Also Published As

Publication number Publication date
CA3087214A1 (en) 2019-07-11
JP2021509809A (ja) 2021-04-08
AU2019205602A1 (en) 2020-07-09
BR112020013790A2 (pt) 2020-12-01
EP3737407A1 (en) 2020-11-18
GB201800274D0 (en) 2018-02-21
RU2020123357A (ru) 2022-01-14
KR20200107958A (ko) 2020-09-16
CN111565743A (zh) 2020-08-21
WO2019135003A1 (en) 2019-07-11
US20200353060A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
MX2020007049A (es) Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CA193736S (en) Skin massager
ZA201705114B (en) Cysteine protease
ZA201705113B (en) Cysteine protease
AU2018260800A1 (en) Hepcidin analogues and uses therof
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2019009443A (es) Metodos para tratar la influenza.
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
MX2016009850A (es) Tratamientos novedosos.
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
MX2018000984A (es) Terapias de combinacion.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
SG11201909851SA (en) Peptide for inducing regeneration of tissue, and use thereof
PH12017501918A1 (en) Multi-peptide composition